Level Four Advisory Services’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
RI
EC
FAM
Level Four Advisory Services's ACAD Position: Q4 2023 in Review
Level Four Advisory Services sold out of Acadia Pharmaceuticals (ACAD) in Q4 2023, closing a stake of 17,565 shares — an estimated $366K sold.
Level Four Advisory Services first reported a position in ACAD in Q3 2023 and held it in 1 quarter. The position peaked at $366K in Q3 2023. 276 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.
- Level Four Advisory Services reported no remaining Acadia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
- Level Four Advisory Services sold 17,565 Acadia Pharmaceuticals shares in Q4 2023, an estimated $366K.
- Level Four Advisory Services first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 1 quarter.
- Level Four Advisory Services's Acadia Pharmaceuticals position peaked at $366K in Q3 2023.
- 276 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.
Based on Level Four Advisory Services's 13F filing for Q4 2023, filed 8 Feb 2024.